蛋白酶抑制剂(药理学)
药代动力学
药理学
病毒学
体内
加药
冠状病毒
虚拟筛选
药物发现
2019年冠状病毒病(COVID-19)
抗病毒药物
化学
离体
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
药品
大流行
病毒
体外
医学
病毒载量
疾病
生物
生物化学
内科学
传染病(医学专业)
抗逆转录病毒疗法
生物技术
作者
Yuto Unoh,Shota Uehara,Kenji Nakahara,Haruaki Nobori,Yukiko Yamatsu,Shiho Yamamoto,Yuki Maruyama,Yoshiyuki Taoda,Koji Kasamatsu,Takahiro Suto,Kensuke Kouki,Atsufumi Nakahashi,Sho Kawashima,Takao Sanaki,Shinsuke Toba,Kentaro Uemura,Tohru Mizutare,Shigeru Ando,Michihito Sasaki,Yasuko Orba
标识
DOI:10.1021/acs.jmedchem.2c00117
摘要
High Resolution Image Download MS PowerPoint Slide The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in millions of deaths and threatens public health and safety. Despite the rapid global spread of COVID-19 vaccines, effective oral antiviral drugs are urgently needed. Here, we describe the discovery of S-217622, the first oral noncovalent, nonpeptidic SARS-CoV-2 3CL protease inhibitor clinical candidate. S-217622 was discovered via virtual screening followed by biological screening of an in-house compound library, and optimization of the hit compound using a structure-based drug design strategy. S-217622 exhibited antiviral activity in vitro against current outbreaking SARS-CoV-2 variants and showed favorable pharmacokinetic profiles in vivo for once-daily oral dosing. Furthermore, S-217622 dose-dependently inhibited intrapulmonary replication of SARS-CoV-2 in mice, indicating that this novel noncovalent inhibitor could be a potential oral agent for treating COVID-19.
科研通智能强力驱动
Strongly Powered by AbleSci AI